Zuranolone
Aug 21, 2023
Mixed Fortunes for Biogen and Sage’ Zuranolone: Approval Under the Cloud of Rejection
In a bittersweet decision for Biogen and Sage Therapeutics, the FDA approved the fast-acting drug zuranolone as the first tablet for postpartum depression on 04 August —but rejected the drug for major depressive disorder treatment. Zurzuvae is a neuroactive steroid that acts as a GABA-A receptor-positive allosteric...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
